Alzheimer’s Drug with Modest Benefits Gets Green Light from FDA Advisers

The drug donanemab slows progression of symptoms in people with early stages of Alzheimer’s disease, but questions linger about the durability of its effect

 The drug donanemab slows progression of symptoms in people with early stages of Alzheimer’s disease, but questions linger about the durability of its effect  Scientific American Content: Global